Cellular Health Screening Market 2030 | Analysis, Size, Share, Growth, Trends and Forecast
Global Cellular Health Screening Market Overview
The global cellular
health screening market was valued at approximately US$ 2.6
billion in 2022 and is projected to grow at a compound annual growth rate
(CAGR) of around 9% over the next five years. Market growth is primarily driven
by increasing government initiatives focused on preventive healthcare, rapid
expansion of the geriatric population, rising funding and investments in
research and development, growing adoption of direct-to-consumer testing
models, and the expanding role of cellular health screening in personalized
medicine. Additionally, the increasing global burden of chronic diseases
continues to support market expansion.
Download Sample Copy: https://meditechinsights.com/cellular-health-screening-market/request-sample/
Cellular health screening, also known as cellular
testing, evaluates overall health at the cellular level by assessing factors
such as lifestyle, environmental exposure, emotional well-being, and diet.
These tests are widely used to assess inflammatory conditions, including
allergies, asthma, arthritis, autoimmune disorders, and inflammatory gastrointestinal
diseases. Cellular health screening also plays a key role in monitoring patient
progress during treatment by providing detailed, data-driven insights into
improvements at the cellular level. Key parameters assessed include cellular
function and integrity, fat mass, intracellular and extracellular fluid levels,
cellular toxicity, and muscle mass.
Rapid
Technological Advancements Driving Market Demand:
Continuous technological advancements in cellular
health screening have led to the development of more efficient, user-friendly,
and accurate diagnostic tests. Innovations such as automated telomere
detection, faster turnaround times, and enhanced analytical precision have
provided manufacturers with a competitive advantage. As a result, leading market
players are increasingly focusing on new product development to strengthen
their market position.
Notable technological advancements include:
- December 2022: Regenerus Labs launched TruAge Complete,
an advanced epigenetic test offering comprehensive insights into
biological aging. The test report includes epigenetic biological age,
telomere length, DunedinPACE, intrinsic and extrinsic epigenetic age,
immune cell-type ratios (CD4:CD8), and predicted response to caloric
restriction.
- August 2022: Proteomics International Laboratories announced
the spin-off of OxiDx Pty Ltd to commercialize its patented “2-tag”
technology, developed in collaboration with The University of Western
Australia, for measuring oxidative stress.
- July 2022: Bloom Diagnostics introduced the Bloom
Inflammation Test, a quantitative C-reactive protein (CRP) test
designed for rapid inflammation assessment in adults using the Bloom
system.
- September 2021: Genomic Vision launched TeloSizer, a novel
solution for automated telomere length detection and quantification based
on proprietary molecular combing technology.
Download Sample Copy: https://meditechinsights.com/cellular-health-screening-market/request-sample/
Increasing Research Activities Fueling Innovation:
The growth of the cellular health screening market is
further supported by increasing research activity and public awareness
initiatives aimed at early disease detection and prevention. Rising demand for
advanced diagnostic tools has encouraged researchers to develop novel and more
precise cellular health screening technologies.
Key research developments include:
- February 2023: Scientists from Duke-NUS Medical School, in
collaboration with institutions in Singapore, China, and the US, developed
a test capable of rapidly and accurately measuring the length of a single
telomere, offering potential as a predictive biomarker for aging and
disease.
- March 2021: Researchers from Queen Mary University of London
and Cardiff University developed a high-throughput single telomere length
analysis (HT-STELA) blood test for diagnosing telomeropathies, applicable
to both fresh and frozen blood samples.
Preventive
Healthcare Initiatives Creating Growth Opportunities:
Preventive healthcare initiatives are expected to
generate significant growth opportunities for the cellular health screening
market. According to a 2020 NCBI report, only 8% of Americans undergo routine
preventive health screenings, a trend mirrored globally. This gap highlights
the growing need for accessible and innovative diagnostic solutions.
Key initiatives include:
- June 2022: The Office of Disease Prevention and Health
Promotion (ODPHP) launched the Take Good Care campaign to promote
age- and condition-appropriate preventive services using the
MyHealthfinder tool.
- October 2021: US Senators introduced bipartisan legislation to
promote preventive healthcare services, including routine physical
examinations and cancer screenings, with a focus on rural and underserved
communities.
North America to Dominate the Market:
North America is expected to account for a significant
share of the global cellular health screening market. This dominance is
attributed to high health awareness, strong demand for preventive healthcare,
early adoption of advanced diagnostic technologies, a rising burden of chronic
and infectious diseases, and a well-established healthcare infrastructure.
For example, in September 2020, Genova Diagnostics
partnered with Rocky Mountain Analytical, a subsidiary of LifeLabs, to improve
access to diagnostic testing across Canada. Additionally, data from the US
Centers for Disease Control and Prevention (CDC) indicate that approximately
six in ten US adults suffer from at least one chronic disease, further driving
demand for preventive diagnostic solutions.
Browse Report: https://meditechinsights.com/cellular-health-screening-market/
Market
Outlook and Competitive Landscape:
The global cellular health screening market is expected
to maintain strong growth momentum due to increasing emphasis on innovation,
rising acceptance of preventive healthcare, a rapidly aging global population,
and ongoing geographic expansion by key market players. By 2030, one in six
individuals worldwide is projected to be aged 60 years or older, increasing the
prevalence of chronic conditions and the demand for preventive diagnostic
testing.
The competitive landscape includes several
well-established players, such as:
- Quest Diagnostics (US)
- Telomere Diagnostics (US)
- SpectraCell Laboratories (US)
- Genova Diagnostics (US)
- LabCorp Holdings (US)
- Repeat Diagnostics, Inc. (Canada)
- Life Length (Spain)
Related Report:
· Nanomedicine
Market - https://www.pharmiweb.com/press-release/2025-12-04/nanomedicine-market-insights-and-growth-opportunities-in-2025-an-extensive-analysis-2030
· Alzheimer’s
Drugs Market - https://www.pharmiweb.com/press-release/2025-12-04/weight-management-market-trends-investment-opportunities-and-growth-analysis-through-2030
· Healthcare
Cloud Computing Market - https://www.pharmiweb.com/press-release/2025-12-04/healthcare-cloud-computing-market-set-to-witness-significant-growth-by-2025-2030
· Weight
Management Market - https://www.pharmiweb.com/press-release/2025-12-04/weight-management-market-trends-investment-opportunities-and-growth-analysis-through-2030
About Medi-Tech Insights;
Medi-Tech Insights is a healthcare-focused business research &
insights firm. Our clients include Fortune 500 companies, blue-chip investors
& hyper-growth start-ups. We have completed 100+ projects in Digital
Health, Healthcare IT, Medical Technology, Medical Devices & Pharma
Services in the areas of market assessments, due diligence, competitive
intelligence, market sizing and forecasting, pricing analysis &
go-to-market strategy. Our methodology includes rigorous secondary research
combined with deep-dive interviews with industry-leading CXO, VPs, and key demand/supply
side decision-makers.
Contact:
Ruta Halde
Associate, Medi-Tech Insights
+32 498 86 80 79
Comments
Post a Comment